NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Since no one corrected me, allow me to self administer:

AND PERHAPS IF NWBO had recourse to a SEASONED PH3 FDA Clinical Regulatory Affairs Specialist as I've been citing, BEFORE 2015, none of which I see in two major 2016 NWBO press releases below... a screening halt may have been avoided??
1)May 2016 The new Scientific Advisory Board as seen HERE:http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123519409
or
2)Jan 2016 new Bd of Dir Susan Bayh:DNDN and Wellpoint Bd of Dir.

FWIW:These two NWBO individuals are apparently delegated that role although IMHO very short of what I've described in terms of demonstrated experience with successful PH3 clinicals: Chief Medical Officer or more importantly FDA Regulatory Affairs, Clinical Trials:

https://www.linkedin.com/in/meghan-swardstrom-246b67?authType=name&authToken=DLPK&trk=prof-sb-browse_map-name
Since 2011 to present Maghan Swardstrom Snr Director of Clinical Develpmt + Operations
2006-2009 Gilead Sciences

https://www.linkedin.com/in/kevinlye?authType=name&authToken=Adpl&trk=prof-sb-browse_map-name
Jan 2015 VP of Medical Affairs Kevin Lye in Honolulu? 9 yrs